Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in...

Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary
Judgment in Ultracet(R) ANDA Patent Litigation

DETROIT, Aug. 27 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories,
Ltd. (NYSE Amex: CPD) announced today that a US Federal Circuit Court has
reversed a portion of a previously decided summary judgment on ANDA Patent
litigation between Ortho McNeil and Caraco regarding Ultracet(R). The court
has remanded the litigation to a lower court for further proceedings. The
court did find that a portion of the patent was not valid. Caraco believes in
the merits of its case and is evaluating its further options.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,
manufactures, markets and distributes generic and private-label
pharmaceuticals to the nation's largest wholesalers, distributors, drugstore
chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made
pursuant to the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. Without limitation, the words "believe" or "expect" and
similar expressions are intended to identify forward-looking statements. Such
statements are based on management's current expectations and are subject to
risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks and
uncertainties are contained in the Corporation's filings with the Securities
and Exchange Commission, including Part I, Item 1A of our most recent Form
10-K, and include but are not limited to: information of a preliminary nature
that may be subject to adjustment, potentially not obtaining or delay in
obtaining FDA approval for new products, governmental restrictions on the sale
of certain products, development by competitors of new or superior products or
less expensive products or new technology for the production of products, the
entry into the market of new competitors, market and customer acceptance and
demand for new pharmaceutical products, availability of raw materials, timing
and success of product development and launches, dependence on few products
generating majority of sales, product liability claims for which the Company
may be inadequately insured, and other risks identified in this report and
from time to time in our periodic reports and registration statements. These
forward-looking statements represent our judgment as of the date of this
report. We disclaim, however, any intent or obligation to update our
forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Jitendra Doshi, +1-313-556-4104, or Thomas Versosky, +1-313-556-4150, both of
Caraco Pharmaceutical